{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:34:00Z","timestamp":1771875240298,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03118-6","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:21:51Z","timestamp":1740709311000},"page":"1642-1691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparability of Randomized Controlled Trials Evaluating Pharmacological Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Mapping Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Corinne","family":"Le Reun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najeeda","family":"Yasmeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis E.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ostrovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Barion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"10","key":"3118_CR1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/medicina57101080","volume":"57","author":"AM Malik","year":"2021","unstructured":"Malik AM, Tupchong S, Huang S, Are A, Hsu S, Motaparthi K. An Updated review of pemphigus diseases. Medicina (Kaunas). 2021;57(10):1080.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"3118_CR2","doi-asserted-by":"publisher","first-page":"30151","DOI":"10.1038\/s41598-024-78031-z","volume":"14","author":"R Saurabh","year":"2024","unstructured":"Saurabh R, Cani A, Moller M, Busch H. Large-scale global retrospective study on the interaction between ancestry and risk of comorbid autoimmune diseases in patients with pemphigus. Sci Rep. 2024;14(1):30151.","journal-title":"Sci Rep"},{"key":"3118_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.808536","volume":"8","author":"YL Lim","year":"2021","unstructured":"Lim YL, Bohelay G, Hanakawa S, Musette P, Janela B. Autoimmune pemphigus: latest advances and emerging therapies. Front Mol Biosci. 2021;8: 808536.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"3118_CR4","first-page":"37","volume":"6","author":"CA D\u2019Angelis","year":"2013","unstructured":"D\u2019Angelis CA. The pathology of pemphigus: a mini-review. North Am J Med Sci. 2013;6(1):37\u201340.","journal-title":"North Am J Med Sci"},{"issue":"1","key":"3118_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00418-008-0420-0","volume":"130","author":"J Waschke","year":"2008","unstructured":"Waschke J. The desmosome and pemphigus. Histochem Cell Biol. 2008;130(1):21\u201354.","journal-title":"Histochem Cell Biol"},{"key":"3118_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.701809","volume":"8","author":"T Schmitt","year":"2021","unstructured":"Schmitt T, Waschke J. Autoantibody-specific signalling in pemphigus. Front Med (Lausanne). 2021;8: 701809.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"3118_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","volume":"61","author":"W Zhao","year":"2021","unstructured":"Zhao W, Wang J, Zhu H, Pan M. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies. Clin Rev Allergy Immunol. 2021;61(3):351\u201362.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10083","key":"3118_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. The Lancet. 2017;389(10083):2031\u201340.","journal-title":"The Lancet"},{"issue":"6","key":"3118_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bjd.12972","volume":"170","author":"AJ Kanwar","year":"2014","unstructured":"Kanwar AJ, Vinay K, Sawatkar GU, Dogra S, Minz RW, Shear NH, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341\u20139.","journal-title":"Br J Dermatol"},{"key":"3118_CR10","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/ced.15213","volume":"47","author":"N Singh","year":"2022","unstructured":"Singh N, Handa S, Mahajan R, Sachdeva N, De D. Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clin Exp Dermatol. 2022;47:1508\u201316.","journal-title":"Clin Exp Dermatol"},{"key":"3118_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"19","author":"VP Werth","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus Mycophenolate mofetil in patients with pemphigus vulgaris. New Eng J Med. 2021;19:2295.","journal-title":"New Eng J Med."},{"issue":"6","key":"3118_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","volume":"33","author":"M Cholera","year":"2016","unstructured":"Cholera M, Chainani-Wu N. Management of pemphigus vulgaris. Adv Ther. 2016;33(6):910\u201358.","journal-title":"Adv Ther"},{"issue":"4","key":"3118_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"issue":"6","key":"3118_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"3118_CR15","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2011."},{"issue":"2","key":"3118_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"9","key":"3118_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","volume":"27","author":"S Tanaka","year":"2024","unstructured":"Tanaka S, Igarashi A, De Moor R, Li N, Hirozane M, Hong LW, et al. A targeted review of worldwide indirect treatment comparison guidelines and best practices. Value Health. 2024;27(9):1179\u201390.","journal-title":"Value Health"},{"issue":"5","key":"3118_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/jrsm.1653","volume":"14","author":"B Truong","year":"2023","unstructured":"Truong B, Tran LT, Le TA, Pham TT, Vo TT. Population adjusted-indirect comparisons in health technology assessment: a methodological systematic review. Res Synth Methods. 2023;14(5):660\u201370.","journal-title":"Res Synth Methods"},{"issue":"1","key":"3118_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13643-023-02178-5","volume":"12","author":"F Campbell","year":"2023","unstructured":"Campbell F, Tricco AC, Munn Z, Pollock D, Saran A, Sutton A, et al. Mapping reviews, scoping reviews, and evidence and gap maps (EGMs): the same but different- the \u201cBig Picture\u201d review family. Syst Rev. 2023;12(1):45.","journal-title":"Syst Rev"},{"key":"3118_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13643-016-0204-x","volume":"5","author":"IM Miake-Lye","year":"2016","unstructured":"Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Syst Rev. 2016;5:28.","journal-title":"Syst Rev"},{"issue":"1","key":"3118_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100004","volume":"1","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021;1(1): 100004.","journal-title":"JID Innov"},{"issue":"7","key":"3118_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"3118_CR23","unstructured":"Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 64 (updated October 2023): Cochrane; 2023."},{"issue":"6","key":"3118_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3118_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3118_CR26","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/jid.2010.91","volume":"130","author":"S Beissert","year":"2010","unstructured":"Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Investig Dermatol. 2010;130(8):2041\u20138.","journal-title":"J Investig Dermatol"},{"issue":"11","key":"3118_CR27","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","volume":"142","author":"S Beissert","year":"2006","unstructured":"Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447\u201354.","journal-title":"Arch Dermatol"},{"issue":"4","key":"3118_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","volume":"57","author":"C Chams-Davatchi","year":"2007","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3118_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","volume":"27","author":"C Chams-Davatchi","year":"2013","unstructured":"Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3118_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/bjd.18482","volume":"182","author":"DM Chen","year":"2020","unstructured":"Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111\u20139.","journal-title":"Br J Dermatol"},{"key":"3118_CR31","unstructured":"A clinical trial to compare the effect of low dose with conventional dose of rituximab used in patients of severe pemphigus. ctri.nic.in. 2018. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/10\/015943."},{"key":"3118_CR32","doi-asserted-by":"publisher","unstructured":"Euctr I. A randomized, double-blind study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris. https:\/\/trialsearchwhoint\/Trial2aspx?TrialID=EUCTR2014-000382-41-IT. 2015. Available from: https:\/\/doi.org\/10.1002\/central\/CN-01821792\/full.","DOI":"10.1002\/central\/CN-01821792\/full"},{"key":"3118_CR33","unstructured":"Estudio multic\u00e9ntrico, prospectivo, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y 52 semanas de duraci\u00f3n para evaluar la eficacia y la seguridad del micofen.... EudraCT. 2005. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000526-75"},{"issue":"7","key":"3118_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","volume":"26","author":"D Ioannides","year":"2012","unstructured":"Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3118_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/archderm.136.7.868","volume":"136","author":"D Ioannides","year":"2000","unstructured":"Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136(7):868\u201372.","journal-title":"Arch Dermatol"},{"issue":"Supplement 1","key":"3118_CR36","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.jval.2021.04.1053","volume":"24","author":"A Kapre","year":"2021","unstructured":"Kapre A, Werth VP, Pordeli P, Chen DM. PRO68 patient-reported outcomes in patients with pemphigus vulgaris treated with rituximab in the phase 3 PEMPHIX study. Value Health. 2021;24(Supplement 1):S210.","journal-title":"Value Health"},{"issue":"8","key":"3118_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamadermatol.2022.2149","volume":"158","author":"A Lemieux","year":"2022","unstructured":"Lemieux A, Maho-Vaillant M, Golinski ML, Hebert V, Boyer O, Calbo S, et al. Evaluation of clinical relevance and biological effects of antirituximab antibodies in patients with pemphigus. JAMA Dermatol. 2022;158(8):893\u20139.","journal-title":"JAMA Dermatol"},{"key":"3118_CR38","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jid.2021.01.031","volume":"141","author":"M Maho-Vaillant","year":"2021","unstructured":"Maho-Vaillant M, Perals C, Golinski ML, Hebert V, Caillot F, Mignard C, et al. Rituximab and corticosteroid effect on desmoglein-specific B cells and desmoglein-specific T follicular helper cells in pemphigus. J Investig Dermatol. 2021;141:2132-40.e1.","journal-title":"J Investig Dermatol"},{"key":"3118_CR39","doi-asserted-by":"crossref","unstructured":"Mentink. Erratum: Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial (Archives of Dermatology (2006) 142 (570\u2013576)). Arch Dermatol. 2006;142(8):1014.","DOI":"10.1001\/archderm.142.8.1014"},{"key":"3118_CR40","doi-asserted-by":"publisher","unstructured":"Mentink L, Toth G, Pavlovic M, Cianchini G, Mackenzie M, Jonkman M. Dexamethasone Pulse Versus Placebo on Pemphigus Vulgaris: results of the PEMPULS Trial. Abstract 081. 35th Annual ESDR Meeting 22\u201324th September 2005, T\u00fcbingen, Germany. J Investig Dermatol. 2005;125(3 Suppl):[A14 p.]. Available from: https:\/\/doi.org\/10.1002\/central\/CN-00792580\/full.","DOI":"10.1002\/central\/CN-00792580\/full"},{"issue":"5","key":"3118_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/archderm.142.5.570","volume":"142","author":"LF Mentink","year":"2006","unstructured":"Mentink LF, Mackenzie MW, Toth GG, Laseur M, Lambert FPG, Veeger NJGM, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142(5):570\u20136.","journal-title":"Arch Dermatol"},{"issue":"5","key":"3118_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","volume":"156","author":"C Mignard","year":"2020","unstructured":"Mignard C, Maho-Vaillant M, Golinski M-L, Balaye P, Prost-Squarcioni C, Houivet E, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(5):545\u201352.","journal-title":"JAMA Dermatol"},{"key":"3118_CR43","unstructured":"Mohta A. Management of pemphigus with Rituximab versus Dexamethasone Pulse therapy: a comparative study with special reference to changes in histopathology and direct immunofluorescence. 25th World Congress of Dermatology Singapore2023."},{"key":"3118_CR44","doi-asserted-by":"publisher","unstructured":"Nct. European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus. https:\/\/clinicaltrialsgov\/show\/NCT00127764. 2005. Available from: https:\/\/doi.org\/10.1002\/central\/CN-02013863\/full.","DOI":"10.1002\/central\/CN-02013863\/full"},{"key":"3118_CR45","doi-asserted-by":"publisher","unstructured":"Nct. Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus. https:\/\/clinicaltrialsgov\/show\/NCT00784589. 2008. Available from: https:\/\/doi.org\/10.1002\/central\/CN-01597826\/full.","DOI":"10.1002\/central\/CN-01597826\/full"},{"key":"3118_CR46","doi-asserted-by":"publisher","unstructured":"Nct. Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone. https:\/\/clinicaltrialsgov\/show\/NCT00626678. 2008. Available from: https:\/\/doi.org\/10.1002\/central\/CN-01517317\/full.","DOI":"10.1002\/central\/CN-01517317\/full"},{"key":"3118_CR47","doi-asserted-by":"publisher","unstructured":"Nct. A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV). https:\/\/clinicaltrialsgov\/show\/NCT00683930. 2008. Available from: https:\/\/doi.org\/10.1002\/central\/CN-02017796\/full.","DOI":"10.1002\/central\/CN-02017796\/full"},{"key":"3118_CR48","doi-asserted-by":"publisher","unstructured":"Nct. A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV). https:\/\/clinicaltrialsgov\/show\/NCT02383589. 2015. Available from: https:\/\/doi.org\/10.1002\/central\/CN-01504861\/full.","DOI":"10.1002\/central\/CN-01504861\/full"},{"issue":"5","key":"3118_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","volume":"29","author":"KV Ratnam","year":"1990","unstructured":"Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol. 1990;29(5):363\u20137.","journal-title":"Int J Dermatol"},{"key":"3118_CR50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/ced.12073","volume":"38","author":"VK Sharma","year":"2013","unstructured":"Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659\u201364.","journal-title":"Clin Exp Dermatol"},{"key":"3118_CR51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bjd.19146","volume":"183","author":"N Singh","year":"2020","unstructured":"Singh N, a S, De D, Mahajan R, Sachdeva N. A comparative study to assess the efficacy and cost-efficiency of immunologically targeted lowdose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Br J Dermatol. 2020;183:9.","journal-title":"Br J Dermatol"},{"issue":"10","key":"3118_CR52","first-page":"1225","volume":"13","author":"SY Naseer","year":"2014","unstructured":"Naseer SY, Gill L, Shah J, Sinha AA. Gender-based variability in disease presentation in pemphigus vulgaris. J Drugs Dermatol. 2014;13(10):1225\u201330.","journal-title":"J Drugs Dermatol"},{"key":"3118_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932909","volume":"13","author":"A Song","year":"2022","unstructured":"Song A, Jang J, Lee A, Min SY, Lee SG, Kim SC, et al. Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients. Front Immunol. 2022;13: 932909.","journal-title":"Front Immunol"},{"issue":"1","key":"3118_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","volume":"311","author":"K Balighi","year":"2019","unstructured":"Balighi K, Daneshpazhooh M, Mahmoudi H, Badakhsh M, Teimourpour A, Ehsani AH, et al. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res. 2019;311(1):63\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"3118_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/09546634.2018.1509049","volume":"30","author":"K Balighi","year":"2019","unstructured":"Balighi K, Daneshpazhooh M, Akbari Z, Tavakolpour S, Azimi P, Azizpour A. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. J Dermatolog Treat. 2019;30(4):346\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"3118_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.429","volume":"4","author":"GN Pathak","year":"2024","unstructured":"Pathak GN, Patel K, Wachuku C, Truong TM, Agarwal P, Rao B. Trends in disease severity and quality of life outcome measures in pemphigus clinical trials: a scoping review. Skin Health Dis. 2024;4(5): e429.","journal-title":"Skin Health Dis"},{"issue":"10","key":"3118_CR57","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/jid.2009.72","volume":"129","author":"M Rosenbach","year":"2009","unstructured":"Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404\u201310.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"3118_CR58","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.det.2011.03.009","volume":"29","author":"SN Chee","year":"2011","unstructured":"Chee SN, Murrell DF. Pemphigus and quality of life. Dermatol Clin. 2011;29(3):521\u20135 (xi-ii).","journal-title":"Dermatol Clin"},{"issue":"2","key":"3118_CR59","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.det.2011.11.008","volume":"30","author":"DF Sebaratnam","year":"2012","unstructured":"Sebaratnam DF, Frew JW, Davatchi F, Murrell DF. Quality-of-life measurement in blistering diseases. Dermatol Clin. 2012;30(2):301\u20137 (ix).","journal-title":"Dermatol Clin"},{"key":"3118_CR60","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3389\/fimmu.2019.02571","volume":"10","author":"RL Krain","year":"2019","unstructured":"Krain RL, Kushner CJ, Tarazi M, Gaffney RG, Yeguez AC, Zamalin DE, et al. Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus. Front Immunol. 2019;10:2571.","journal-title":"Front Immunol"},{"issue":"1","key":"3118_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jval.2012.07.003","volume":"16","author":"G Lu","year":"2013","unstructured":"Lu G, Brazier JE, Ades AE. Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model. Value Health. 2013;16(1):177\u201384.","journal-title":"Value Health"},{"key":"3118_CR62","unstructured":"McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter 9: Summarizing study characteristics and preparing for synthesis [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 65: Cochrane; 2024."},{"issue":"2","key":"3118_CR63","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","volume":"73","author":"L Atzmony","year":"2015","unstructured":"Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3118_CR64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaad.2020.08.028","volume":"85","author":"MS Lee","year":"2021","unstructured":"Lee MS, Yeh YC, Tu YK, Chan TC. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2021;85(1):176\u201386.","journal-title":"J Am Acad Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03118-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03118-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03118-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:28:57Z","timestamp":1743121737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03118-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3118"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03118-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Corinne Le Reun, Najeeda Yasmeen, Alexis E. Cullen, and Laura Sawyer are employees of, or independent consults for, Symmetron Limited at the time of analysis\/writing. Symmetron Limited received funding from argenx for design and conduct of this study, data synthesis, and manuscript preparation. Olga Ostrovskaya and Francesca Barion are employees of argenx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}